Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 4/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | GSK3B | P49841 | 5/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
| ▸ | BUB1 | O43683 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706505 | 0.87 | PIK3C3 (0.63) | PIK3C3BRD4CREBBP | |
| SCHEMBL19699587 | 0.84 | PIK3C3 (0.43) | PIK3C3MAPTGSK3BTYK2ABL1 | |
| SCHEMBL16105613 | 0.81 | CSNK1D (0.58) | ABL1EGFR | |
| SCHEMBL19699521 | 0.75 | DYRK1A (0.48) | PIK3C3MAPTGSK3BTYK2BUB1 | |
| SCHEMBL19699553 | 0.74 | DYRK1A (0.57) | BRD4CREBBPGSK3BABL1 | |
| SCHEMBL16105258 | 0.74 | CSNK1D (0.58) | EGFR | |
| SCHEMBL19699579 | 0.73 | MAPK14 (0.49) | PIK3C3MAPTGSK3BTYK2RIPK3 | |
| SCHEMBL19962827 | 0.73 | MAPT (0.53) | MAPTGSK3BTYK2 | |
| SCHEMBL1646401 | 0.72 | MAPK14 (0.47) | MAPTGSK3BABL1RIPK3 | |
| SCHEMBL16105680 | 0.71 | CSNK1D (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PIK3C3 4720/4885BRD4 429/4885CREBBP 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.